4.7 Article

Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 140, Issue 5, Pages 1388-+

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2016.12.978

Keywords

Primary immunodeficiencies; autoimmunity; inflammation

Funding

  1. French Association of Patients with Primary Immunodeficiencies (IRIS)
  2. French Ministry of Health
  3. LFB
  4. GlaxoSmithKline
  5. CSL Behring
  6. Baxalta
  7. Octapharma
  8. Binding Site
  9. patient association AT-Europe
  10. patient association Trophee Guillaume

Ask authors/readers for more resources

Background: Primary immunodeficiencies (PIDs) are inherited diseases associated with a considerable increase in susceptibility to infections. It is known that PIDs can also predispose to cancer and immune diseases, including allergy, autoimmunity, and inflammation. Objective: We aimed at determining the incidence of autoimmunity and inflammation in patients with PIDs. Methods: We have retrospectively screened 2183 consecutive cases of PID in the Centre de Reference Deficits Immunitaires Hereditaires registry (CEREDIH; the French national PID registry) for the occurrence of autoimmunity and inflammation. Results: One or more autoimmune and inflammatory complications were noted in 26.2% of patients, with a risk of onset throughout the patient's lifetime. The risk of autoimmune cytopenia was at least 120 times higher than in the general population, the risk of inflammatory bowel disease in children was 80 times higher, and the risk of other autoimmune manifestations was approximately 10 times higher. Remarkably, all types of PIDs were associated with a risk of autoimmune and inflammatory complications, although the greatest risk was associated with T-cell PIDs and common variable immunodeficiency. The occurrence of autoimmune disease is a negative prognostic factor for survival. Conclusions: Our results provide the basis for a detailed prospective evaluation of autoimmunity and inflammation in the context of PIDs, with a view to accurately assessing these risks and describing the possible effect of medical intervention.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available